Cholangiocarcinoma

Showing 26 - 50 of 287

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable Trial in Boston (Gemcitabine, Cisplatin, Durvalumab)

Not yet recruiting
  • Bile Duct Cancer
  • +4 more
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 23, 2023

Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer Trial run by the National Cancer

Recruiting
  • Metastatic Colorectal Cancer (Mcrc)
  • +7 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

Cholangiocarcinoma, Gall Bladder Carcinoma Trial in Worldwide (Gemcitabine, Cisplatin, Capecitabine)

Active, not recruiting
  • Cholangiocarcinoma
  • Gall Bladder Carcinoma
  • Bankstown, New South Wales, Australia
  • +66 more
Jan 22, 2023

l Science Network of Precision-based Immunotherapy for Primary

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
    • La Jolla, California
    • +6 more
    Jan 24, 2023

    Advanced Cancer, Anal Carcinoma, Anal Cancer Trial in Worldwide (pembrolizumab)

    Recruiting
    • Advanced Cancer
    • +24 more
    • pembrolizumab
    • Los Angeles, California
    • +21 more
    Jan 18, 2023

    Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

    Recruiting
    • Minimal Residual Disease
    • +11 more
    • ELI-002 2P
    • Duarte, California
    • +10 more
    Jan 18, 2023

    Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Common Bile Duct Tumors Trial in Rotterdam (Endoscopic Ultrasound

    Recruiting
    • Hilar Cholangiocarcinoma
    • +4 more
    • Endoscopic Ultrasound registration
    • Rotterdam, Zuid-Holland, Netherlands
      Erasmus University Medical Center
    Jan 11, 2023

    Biliary Cell-derived Organoids From Bile of PSC and Non-PSC

    Recruiting
    • Primary Sclerosing Cholangitis
    • +2 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Jan 9, 2023

      Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7 Trial in Scottsdale, Rochester

      Active, not recruiting
      • Cholangiocarcinoma
      • +6 more
      • Laboratory Biomarker Analysis
      • Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
      • Scottsdale, Arizona
      • +1 more
      Jan 4, 2023

      Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma Trial in Gainesville, Miami, Orlando (Niraparib)

      Completed
      • Mesothelioma
      • +3 more
      • Gainesville, Florida
      • +2 more
      Jan 4, 2023

      Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

      Recruiting
      • Cholangiocarcinoma
      • +4 more
      • Anchorage, Alaska
      • +16 more
      Jan 3, 2023

      Cholangiocarcinoma Trial in Düsseldorf (Combination of Lonsurf® and Irinotecan)

      Recruiting
      • Cholangiocarcinoma
      • Combination of Lonsurf® and Irinotecan
      • Düsseldorf, NRW, Germany
        Klinik für Gastroenterologie, Hepatologie und Infektiologie
      Dec 22, 2022

      Cholangiocarcinoma Trial (Carrilizumab, Albumin-bound paclitaxel, Apatinib)

      Not yet recruiting
      • Cholangiocarcinoma
      • (no location specified)
      Dec 9, 2022

      Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma Trial in United States (STP705)

      Active, not recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • Scottsdale, Arizona
      • +4 more
      Dec 13, 2022

      Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer Trial in Sydney, Hong Kong (ARB202)

      Recruiting
      • Gastrointestinal Cancer
      • +5 more
      • Adelaide, Australia
      • +3 more
      Dec 13, 2022

      Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer Trial ([18F]FAPI-74 PET/CT)

      Not yet recruiting
      • Gastrointestinal Cancers
      • +5 more
      • [18F]FAPI-74 PET/CT
      • (no location specified)
      Nov 29, 2022

      Drug Sensitivity of Patient-Derived Organoid Model From

      Recruiting
      • Cholangiocarcinoma
      • No interventions.
      • Guangzhou, Guangdong, China
        Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      Nov 29, 2022

      Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer Trial in United States (NC318)

      Active, not recruiting
      • Advanced or Metastatic Solid Tumors
      • +8 more
      • Los Angeles, California
      • +5 more
      Nov 29, 2022

      Cholangiocarcinoma, Bile Duct Cancer Trial in Toronto (Trifluridine/Tipiracil)

      Terminated
      • Cholangiocarcinoma
      • Bile Duct Cancer
      • Toronto, Ontario, Canada
        Sunnybrook Health Sciences Centre
      Nov 28, 2022

      Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

      Completed
      • Melanoma
      • +27 more
      • XmAb20717
      • Los Angeles, California
      • +16 more
      Nov 29, 2022

      Cholangiocarcinoma Trial in Ann Arbor (KSP/QRH dimer)

      Terminated
      • Cholangiocarcinoma
      • KSP/QRH dimer
      • Ann Arbor, Michigan
        Michigan Medicine
      Nov 17, 2022

      Cholangiocarcinoma Trial (Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy)

      Not yet recruiting
      • Cholangiocarcinoma
      • Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy
      • (no location specified)
      Nov 10, 2022

      Prospective Evaluation of Biliary Tissue Sampling With ERCP

      Enrolling by invitation
      • Cholangiopancreatography, Endoscopic Retrograde
      • +3 more
        • Rochester, Minnesota
          Mayo Clinic in Rochester
        Nov 7, 2022

        Pancreatic Cancer, Cholangiocarcinoma, Gallbladder Cancer Trial in Seoul (cell free DNA in blood and urine,

        Recruiting
        • Pancreatic Cancer
        • +2 more
        • cell free DNA in blood and urine, metabolite/microbiome in urine and stool
        • Seoul, Korea, Republic of
        • +1 more
        Nov 2, 2022